Biotecnol Corporate Presentation

Therapies for life

José Luís Moreira, Ph.D., MBA Chief Financial Officer & Chief Operational Officer

Development of new drugs

Development of new drugs

Research

institutions

Development of new drugs

Multinational pharma corps.

Development of new drugs

Multinational pharma corps.

Development of new drugs

Biotec sme’s

Biotecnol

Core Business

7

proprietary products

strategy (long term)

services

tactics (short term)

new pharma products

oncology

MoABs

Biotecnol

● improved products to known targets

● new products to new targets

2003 – ...

technologies platforms

partnerships

processes

products

know-how

● services to other

companies

● production of their own

products

● optimization of

production process

● as a service supply or in

partnership

Biotecnol

hepathology

8

Core Business

1998 – ...

Corporate Organization

inc

sa

sasa

www.biotecnol.com www.rodonbiologics.com

Rodon Biologics

Corporate Organization

New Brunswick, NJ (USA)

Oeiras (Portugal)

Non Tribody services to 3rd parties

Subcontracted Tribody

development services

Potential Biotecnol SA competitors

Highly qualified and experienced

scientists

Fully equipped laboratories

Out-licensing and own Tribody pipeline

Rodon Biologics

Tribody Platform IP US management Know-How Protocols SOP’s Commercial and

R&D contracts

Third party outsourcing

Site in Oeiras, PT

• Process development and manufacturing • Quality Control System

Site in New Brunswick, NJ

• Preclinical development

• Future clinical development

Corporate Organization

State of the art R&D centre

• First Portuguese biopharmaceutical company to establish its activity outside a public R&D institute and become fully independent • Full internal capabilities for biological products development and manufacturing

State of the art R&D centre

Effective process development

PROCESS

DEVELOPMENT

Economics

Business

Technology

Manufacturing

Engineering

Scale-up

Quality Control

Quality Assurance

Regulatory Affairs Supply Chain and Logistics

Naples University

Collaboration and technology licensing

3rd party services

3rd party services

IL-13

Cardiotrophin1

VB6-845-CL

GMCFS

Interferon

Bavituximab

ACE393

NS3

Uvidem®

transplants

oncology

stroke

ACV

HCV

vaccine

Hepatitis C

Anti-Hsp90

FastScreen

metastatic melanoma

ADC-1004 Stroke, trauma

Product Partner Indication R&D Pre-clinic Phase

I Phase

III Phase

II

Pro.insulin Retinitis pigmentosa

Tribody Platform

dual antigen target molecules‏

single antigen target molecules

CD19 CD19 CD20 CD20 XX

CD3CD3 CD3

CD19 CD19 CD20 CD20 XXCD19 CD19 CD20 CD20 XX

CD3CD3 CD3

CD20CD19

CD3

XCD19

CD3

CD20 X

CD3

CD20CD19

CD3

XCD19

CD3

CD20 X

CD3

CD20CD19

CD3

CD20CD19

CD3

XCD19

CD3

XCD19

CD3

CD20 X

CD3

CD20 X

CD3

19

Contacts

Biotecnol, SA

Lagoas Park

Edifício 7,1º Norte

2741-901 Oeiras

Portugal

Biotecnol Pharmaceuticals, Inc

675 US Highway OneNorth Brunswick, NJ 08902 USA USA

jlm@biotecnol.com

www.biotecnol.com

www.rodonbiologics.com